ARDELYX, INC.

ARDX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $-16.7M $-37.6M $-407.0K $-969.0K $-19.1M $-41.1M $4.6M $-809.0K
Depreciation & Amortization $604.0K $915.0K $921.0K $905.0K $631.0K $602.0K $515.0K $544.0K
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $15.3M $14.2M $12.4M $12.7M $11.7M $12.1M $9.9M $9.1M
Net Cash from Operating Activities $-6.4M $-32.2M $21.0M $365.0K $-25.3M $-38.5M $9.8M $501.0K
Investing Activities
Capital Expenditures $13.0K $69.0K $361.0K $156.0K $650.0K $325.0K $593.0K $137.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $22.7M $-10.0M $3.8M $-50.5M $34.9M $2.9M $-41.6M $2.3M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $49.7M $5.4M $557.0K $2.8M $49.7M $1.5M $49.3M $2.7M
Net Change in Cash $66.0M $-36.8M $25.3M $-47.3M $59.2M $-34.1M $17.5M $5.5M
Free Cash Flow $-6.4M $-32.3M $20.6M $209.0K $-26.0M $-38.8M $9.2M $364.0K
← Newer Page 1 of 7 Older →